Company Filing History:
2 out of 2,893 
2 out of 2,963 
Years Active: 2017-2021
Title: Lev Silberstein: Innovator in Hematopoietic Research
Introduction
Lev Silberstein is a prominent inventor based in Brookline, MA (US), known for his significant contributions to the field of hematopoietic research. He holds 2 patents that focus on enhancing hematopoietic reconstitution, which is crucial for patients undergoing stem cell therapies.
Latest Patents
Silberstein's latest patents include innovative methods for promoting hematopoietic stem and progenitor cell expansion. One patent details the use of Embigin inhibition to enhance hematopoietic reconstitution in subjects. This method involves administering a therapeutically effective amount of an Embigin inhibitor to a recipient, potentially alongside hematopoietic stem/progenitor cells. Another patent focuses on IL-18 inhibition, which similarly aims to enhance hematopoietic reconstitution by administering an IL-18 inhibitor to both the recipient and the donor prior to cell harvest. Both patents also describe pharmaceutical compositions related to these methods.
Career Highlights
Throughout his career, Lev Silberstein has worked with esteemed institutions such as The General Hospital Corporation and Harvard College. His work has significantly advanced the understanding and application of hematopoietic stem cell therapies.
Collaborations
Silberstein has collaborated with notable colleagues, including David T. Scadden and Peter Kharchenko, contributing to the advancement of research in his field.
Conclusion
Lev Silberstein's innovative work in hematopoietic research and his patented methods for enhancing stem cell therapies highlight his important role in the scientific community. His contributions continue to pave the way for advancements in medical treatments.